Pyrazoloadenine

Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity[1][2].

Product Specifications

CAS Number

[2380-63-4]

UNSPSC

12352005

Hazard Statement

H301, H315, H319, H335

Target

RET

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pyrazoloadenine.html

Purity

99.98

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC1=C2C(NN=C2)=NC=N1

Molecular Formula

C5H5N5

Molecular Weight

135.13

Precautions

H301, H315, H319, H335

References & Citations

[1]Saha D, et al. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. ChemMedChem. 2021 May 18;16 (10) :1605-1608.|[2]SKIPPER HE, et al. Inhibition of experimental neoplasms by 4-aminopyrazolo (3, 4-d) pyrimidine. Proc Soc Exp Biol Med. 1955 Aug;89 (4) :594-6.